2025
CAPTAIN RANDOMIZED CONTROLLED TRIAL OF TULSA AGAINST RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: DESIGN AND RECRUITMENT UPDATE
Meng X, Lotan Y, Kella N, Koch M, Pavlovich C, George A, Michel K, Sprenkle P, Sonn G, Mynderse L, Anttinen M, Chin J, Inman B, Mehan R, Banapour P, Sharif-Afshar A, Woodrum D, Ghanouni P, Arora S, Macura K, Princenthal R, Cohen M, Staruch R, Clarke G, Costa D, Klotz L. CAPTAIN RANDOMIZED CONTROLLED TRIAL OF TULSA AGAINST RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: DESIGN AND RECRUITMENT UPDATE. Urologic Oncology Seminars And Original Investigations 2025, 43: 79. DOI: 10.1016/j.urolonc.2024.12.200.Peer-Reviewed Original ResearchRadical prostatectomyRandomized controlled trialsProstate cancerAblation therapyAlternative to radiation therapyLocalized prostate cancerPCa-specific deathPad-free continencePrimary safety endpointPoor patient acceptanceStandard of careOrgan-confinedProstatectomy groupSignificant functional impairmentMetastatic diseaseRadiation therapyOpen-labelEfficacy endpointSecondary endpointsSafety endpointsSurgical approachPivotal studiesEfficacy dataNon-inferioritySub-sitesThe Central Vein Sign as a Radiologic Tool to Predict the Diagnosis of Radiation Necrosis in Intracranial Metastatic Cancer Patients
Antonios J, Adenu-Mensah N, Theriault B, Millares-Chavez M, Huttner A, Aboian M, Chiang V. The Central Vein Sign as a Radiologic Tool to Predict the Diagnosis of Radiation Necrosis in Intracranial Metastatic Cancer Patients. Clinical And Translational Neuroscience 2025, 9: 10. DOI: 10.3390/ctn9010010.Peer-Reviewed Original ResearchCentral vein signRadiation necrosisTumor progressionDiagnosis of radiation necrosisDifferentiate RNCerebral radiation necrosisIntracranial metastatic diseaseCancer therapy responseMetastatic cancer patientsNon-invasive markerMetastatic diseaseSurgical biopsyTherapy responsePredictive markerPatient cohortPrimary treatmentRadiological toolsCancer patientsRadiological imagingTreatment decisionsPerivascular spacesPatientsTreatmentNecrosisMarkersComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, jnumed.124.267927. PMID: 39947910, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsTime to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial.
Sayegh N, Jo Y, Swami U, Hage Chehade C, Ozay Z, Gebrael G, Maughan B, Plets M, Hussain M, Dorff T, Lara P, Goldkorn A, Lerner S, Agarwal N. Time to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial. Journal Of Clinical Oncology 2025, 43: 173-173. DOI: 10.1200/jco.2025.43.5_suppl.173.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalOverall survivalMetachronous diseaseMetastatic hormone-sensitive prostate cancerInitial prostate cancer diagnosisTiming of metastatic diseaseHormone-sensitive prostate cancerSubgroups of ptsTime of prostatectomyTime to metastasisCox proportional hazards modelsProstate cancer diagnosisProportional hazards modelDeprivation therapyGleason scoreMetastatic diseaseMetastatic recurrenceMetastatic diagnosisPrognostic factorsPerformance statusProstate cancerPrognostic valueSurvival outcomesProstatectomyComprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas
Antony V, Sun T, Dolezal D, Cai G. Comprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas. Cancers 2025, 17: 335. PMID: 39941707, PMCID: PMC11815932, DOI: 10.3390/cancers17030335.Peer-Reviewed Original ResearchMetastatic pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaPrimary pancreatic ductal adenocarcinomaMolecular profilingGene mutationsGene copy number alterationsAdvanced-stage pancreatic cancerInsufficient tumor cellsOncomine Comprehensive AssayRate of TP53Copy number alterationsMetastatic diseasePDAC casesPIK3CA mutationsPancreatic cancerPoor prognosisTreatment optionsDuctal adenocarcinomaTumor cellsTumor progressionMolecular alterationsStudy cohortMolecular testingComprehensive assayTherapeutic targetFamitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Ai L, Li Q, Zhang S, Dong Y, Yang M, Li J, Pan Y, Yuan Y, Yi S, Wang J, Cheng Y, Feng J, Gao S, Wang X, Qu S, Zhang X, Lu J, Xiu P, Wang S, Yang X, Yu Y, Liu T. Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study. The Innovation 2025, 6: 100745. PMID: 39872476, PMCID: PMC11763884, DOI: 10.1016/j.xinn.2024.100745.Peer-Reviewed Original ResearchProgression-free survivalDuration of responseAdvanced colorectal cancerOverall survivalColorectal cancerMedian duration of responseMedian progression-free survivalMetastatic colorectal cancer patientsTreatment-related adverse eventsMedian follow-up timeMedian overall survivalMetastatic solid tumorsPD-1 antagonistsFollow-up timeCohort of patientsAnti-angiogenic agentsColorectal cancer patientsInhibition of angiogenesisPD-1Immune checkpointsMetastatic diseaseBasket studyMedian durationPrimary endpointSystemic treatment
2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Shroff R, King G, Colby S, Scott A, Borad M, Goff L, Matin K, Mahipal A, Kalyan A, Javle M, Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean E, Hochster H, Philip P. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Journal Of Clinical Oncology 2024, 43: 536-544. PMID: 39671534, PMCID: PMC11798714, DOI: 10.1200/jco-24-01383.Peer-Reviewed Original ResearchProgression-free survivalBiliary tract cancerAdvanced biliary tract cancerOverall survivalGallbladder carcinomaExtrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaHazard ratioNab-paclitaxelMedian progression-free survivalMetastatic biliary tract cancerProgression-free survival benefitPhase III randomized trialGemcitabine-cisplatin regimenTrial of gemcitabineLocally advanced diseaseExploratory subset analysisDiagnosing BTCEvaluated gemcitabineMedian OSMetastatic diseaseAdvanced diseaseNo significant differenceSubset analysisGemcitabineSetdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma.
McGeary M, Damsky W, Daniels A, Lang S, Xu Q, Song E, Huet-Calderwood C, Lou H, Paradkar S, Micevic G, Kaech S, Calderwood D, Turk B, Yan Q, Iwasaki A, Bosenberg M. Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma. Cancer Immunology Research 2024, 13: 245-257. PMID: 39589394, DOI: 10.1158/2326-6066.cir-23-0514.Peer-Reviewed Original ResearchT cell infiltrationMHC-I expressionType I interferonImmune clearanceCD8+ T cell-dependent mannerIncreased CD8+ T cell infiltrationCD8+ T cell infiltrationDecreased MHC-I expressionAnti-cancer immune responseT cell-dependent mannerCD8+ T cellsDecreased T-cell infiltrationComplete tumor clearanceImmunity to melanomaIncreased melanoma growthInflamed tumor microenvironmentLoss of SETDB1Type I interferon receptorTreatment of melanomaType I interferon signalingWhole-genome CRISPR screenEndogenous retrovirusesType I interferon expressionMetastatic diseaseTumor clearanceGastric Cancer at a Nigerian Tertiary Referral Center: Experiences With Establishing an Institutional Cancer Registry
Yibrehu B, Mohammed T, Murthy S, Aderibigbe A, Daramola O, Arije O, Owoade I, Wuraola F, Olasehinde O, Betiku O, Folorunso S, Omoyiola O, Aderounmu A, Adisa A, Kingham P, Alatise O. Gastric Cancer at a Nigerian Tertiary Referral Center: Experiences With Establishing an Institutional Cancer Registry. Journal Of Surgical Oncology 2024 PMID: 39558548, DOI: 10.1002/jso.27993.Peer-Reviewed Original ResearchInstitutional cancer registryGastric cancerCancer RegistryTreatment modalitiesSuspected gastric cancerManagement of gastric cancerQuality of registry dataTertiary referral centerGastric cancer registryHigh-risk patientsDatabase of patientsGastric cancer databasePeriodic chart reviewMetastatic diseaseAdvanced diseaseReferral centerCancer DatabaseAvailability of robust dataMedian timeChart reviewFollow-upDeadly malignancyBlood workPatientsRegistry dataA multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features
Klughammer J, Abravanel D, Segerstolpe Å, Blosser T, Goltsev Y, Cui Y, Goodwin D, Sinha A, Ashenberg O, Slyper M, Vigneau S, Jané‐Valbuena J, Alon S, Caraccio C, Chen J, Cohen O, Cullen N, DelloStritto L, Dionne D, Files J, Frangieh A, Helvie K, Hughes M, Inga S, Kanodia A, Lako A, MacKichan C, Mages S, Moriel N, Murray E, Napolitano S, Nguyen K, Nitzan M, Ortiz R, Patel M, Pfaff K, Porter C, Rotem A, Strauss S, Strasser R, Thorner A, Turner M, Wakiro I, Waldman J, Wu J, Gómez Tejeda Zañudo J, Zhang D, Lin N, Tolaney S, Winer E, Boyden E, Chen F, Nolan G, Rodig S, Zhuang X, Rozenblatt-Rosen O, Johnson B, Regev A, Wagle N. A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features. Nature Medicine 2024, 30: 3236-3249. PMID: 39478111, PMCID: PMC11564109, DOI: 10.1038/s41591-024-03215-z.Peer-Reviewed Original ResearchClinicopathological featuresLocal T cell infiltrationT cell infiltrationMetastatic breast cancerBreast cancer biopsiesCancer-related deathsEpithelial-to-mesenchymal transitionMetastatic diseaseClinically relevant discoveriesTumor biopsiesTumor microenvironmentCancer biopsiesBreast cancerAnatomical sitesMacrophage populationsSingle-nucleus RNA sequencingBiopsyH&E stainingConsecutive serial sectionsClinical annotationTumorSingle-cellSpatial expression characteristicsSerial sectionsCell type compositionAssessing a revised-risk analysis index for morbidity and mortality after spine surgery for metastatic spinal tumors
Elsamadicy A, Serrato P, Sadeghzadeh S, Sayeed S, Hengartner A, Khalid S, Lo S, Shin J, Mendel E, Sciubba D. Assessing a revised-risk analysis index for morbidity and mortality after spine surgery for metastatic spinal tumors. Journal Of Neuro-Oncology 2024, 171: 213-228. PMID: 39320656, DOI: 10.1007/s11060-024-04830-z.Peer-Reviewed Original ResearchModified frailty index-5Length of stayRAI-revMetastatic spinal tumorsPredicting 30-day mortalityReceiver operating characteristicArea under the curveSpine surgeryFrail patientsSpinal tumorsNo significant differenceSpinal pathologyMultivariate analysisMethodsA retrospective cohort studySignificant differenceExtended length of stayReceiver operating characteristic analysisACS NSQIP databasePredictors of extended length of stayRetrospective cohort studyMultidisciplinary decision makingMetastatic diseaseNSQIP databasePatient ageSpinal surgeryModern Management of Gastric Neuroendocrine Neoplasms
Kunstman J, Nagar A, Gibson J, Kunz P. Modern Management of Gastric Neuroendocrine Neoplasms. Current Treatment Options In Oncology 2024, 25: 1137-1152. PMID: 39083164, DOI: 10.1007/s11864-024-01207-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsG-NENsGastrin-secreting tumorsSurgical resectionHeterogeneous group of tumorsProton pump inhibitor usageResection of visible lesionsG-NEN patientsGroup of tumorsRisk of progressionHigh-risk lesionsMetastatic diseaseNeuroendocrine tumorsNeuroendocrine neoplasmsMetastatic spreadEndoscopic resectionEndoscopic surveillanceTreatment paradigmInhibitor usageNeuroendocrine diseaseResectionTumorLow riskVisible lesionsHeterogeneous groupDe-escalationCauses of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era
Lee D, McNamara M, Yang A, Yaskolko M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Pigment Cell & Melanoma Research 2024, 37: 847-853. PMID: 39073002, PMCID: PMC11809125, DOI: 10.1111/pcmr.13188.Peer-Reviewed Original ResearchSite of metastasisPattern of metastatic diseaseMelanoma mortalityRetrospective observational cohort studyCause of cancer mortalityDistant lymph nodesObservational cohort studyDiagnosis to deathImmunotherapy eraAdvanced melanomaMetastatic diagnosisMetastatic diseaseMetastatic melanomaImmunotherapy treatmentRespiratory failureCause of deathMedian timeLymph nodesTherapeutic advancesCohort studyMelanomaImmunotherapyMechanism of deathPatientsEnd of lifeIron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer.
Sandoval T, Salvagno C, Chae C, Awasthi D, Giovanelli P, Marin Falco M, Hwang S, Teran-Cabanillas E, Suominen L, Yamazaki T, Kuo H, Moyer J, Martin M, Manohar J, Kim K, Sierra M, Ramos Y, Tan C, Emmanuelli A, Song M, Morales D, Zamarin D, Frey M, Cantillo E, Chapman-Davis E, Holcomb K, Mason C, Galluzzi L, Ni Zhou Z, Vaharautio A, Cloonan S, Cubillos-Ruiz J. Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer. Cancer Discovery 2024, 14: 1901-1921. PMID: 39073085, PMCID: PMC11452292, DOI: 10.1158/2159-8290.cd-23-1451.Peer-Reviewed Original ResearchNatural killerOvarian cancerFDA-approved iron chelatorIron chelatorsAlternative immunotherapeutic strategyI interferonActivated natural killerSurvival of miceOvarian cancer cellsType I IFN responseProduction of type I interferonsHallmarks of cancerType I interferonImmunostimulatory stateInnate immune responseMetastatic diseaseImmunotherapeutic strategiesOverexpression of moleculesTumor microenvironmentDisease progressionImmunomodulatory effectsImmune responseCancer cellsConcomitant activationDNA damage responseOverexpression of Malat1 drives metastasis through inflammatory reprogramming of the tumor microenvironment
Martinez-Terroba E, Plasek-Hegde L, Chiotakakos I, Li V, de Miguel F, Robles-Oteiza C, Tyagi A, Politi K, Zamudio J, Dimitrova N. Overexpression of Malat1 drives metastasis through inflammatory reprogramming of the tumor microenvironment. Science Immunology 2024, 9: eadh5462. PMID: 38875320, DOI: 10.1126/sciimmunol.adh5462.Peer-Reviewed Original ResearchConceptsTumor microenvironmentLung adenocarcinomaMetastatic diseasePromoting metastatic diseaseGlobal chromatin accessibilityMetastasis-associated lung adenocarcinoma transcript 1Overexpression of MALAT1Lung adenocarcinoma transcript 1Lung adenocarcinoma metastasisCCL2 blockadeInflammatory reprogrammingEnhanced cell mobilityMacrophage depletionMechanism of actionTumor typesTumor progressionMouse modelCell mobilizationTumorLong noncoding RNAsParacrine secretionMetastasisCell linesTranscript 1MicroenvironmentEBUS-TBNA pleural biopsy reveals prostate cancer metastasis: A rare case report and review of the literature
Sampsonas F, Komninos D, Sotiropoulou V, Katsaras M, Gkanetsou D, Papaioannou O, Tsiri P, Tzelepi V, Tzouvelekis A. EBUS-TBNA pleural biopsy reveals prostate cancer metastasis: A rare case report and review of the literature. Pneumon 2024, 37: 1-4. DOI: 10.18332/pne/188870.Peer-Reviewed Original ResearchSPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers.
Pachman D, Ruddy K, Grzegorczyk V, Kroenke K, Griffin J, Ridgeway J, Chlan L, Tofthagen C, Leventakos K, Strand J, Austin J, Smith A, Mitchell S, Herrin J, Cheville A. SPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers. Journal Of Clinical Oncology 2024, 42: 11108-11108. DOI: 10.1200/jco.2024.42.16_suppl.11108.Peer-Reviewed Original ResearchSymptom burdenHigh school educationDiverse sample of patientsAmerican Indian/Alaska Native (AI/ANSymptom management interventionsHigh symptom burdenPhysical function impairmentComposite scoreCancer symptom controlTotal symptom burdenSchool educationComposite mean scoresSymptom interventionMetastatic diseaseMetastatic cancerSymptom prevalenceSample of patientsSymptom surveyEmployment statusDisability statusMean scoreICD codesCancer typesManagement interventionsSymptom controlCauses of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.
Lee D, Yang A, McNamara M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Journal Of Clinical Oncology 2024, 42: e21522-e21522. DOI: 10.1200/jco.2024.42.16_suppl.e21522.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsYale Cancer CenterAdvanced melanomaMetastatic diseaseMetastatic melanomaRespiratory failureSite of metastatic diseasePattern of metastatic diseaseDied of respiratory failureAnti-CTLA4 treatmentRetrospective observational cohort studyAnti-PD1 therapyDistant lymph nodesPatients aged >Site of diseaseSurvival of patientsObservational cohort studyMulti-system involvementDiagnosis to deathImmunotherapy eraAnti-PD1Checkpoint inhibitorsInstitutional review boardMetastatic sitesMetastatic diagnosisThe Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms
Chen A, Sharma N, Patel P, Olivares S, Bahrami A, Barnhill R, Blokx W, Bosenberg M, Busam K, de La Fouchardière A, Duncan L, Elder D, Ko J, Landman G, Lazar A, Lezcano C, Lowe L, Maher N, Massi D, Messina J, Mihic-Probst D, Parker D, Redpath M, Scolyer R, Shea C, Spatz A, Tron V, Xu X, Yeh I, Yun S, Zembowicz A, Gerami P. The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms. The American Journal Of Surgical Pathology 2024, 48: 708-718. PMID: 38590014, DOI: 10.1097/pas.0000000000002226.Peer-Reviewed Original ResearchConceptsDesmoplastic melanomaMelanocytic neoplasmsNext-generation sequencingInterobserver agreementDiagnostic accuracyHematoxylin and eosin sectionsImpact of next-generation sequencingDiagnostic scenariosMetastatic diseaseDesmoplastic tumorsMelanocytic tumorsMelanoma casesMelanoma geneticsFleiss' multirater kappaAccurate diagnosisNeoplasmsMelanomaAncillary toolDegree of improvementMultirater kappaDiagnosisGenomic findingsTumorGenome sequencing resultsPathologistsMLL1 regulates cytokine-driven cell migration and metastasis
Nair P, Danilova L, Gómez-de-Mariscal E, Kim D, Fan R, Muñoz-Barrutia A, Fertig E, Wirtz D. MLL1 regulates cytokine-driven cell migration and metastasis. Science Advances 2024, 10: eadk0785. PMID: 38478601, PMCID: PMC10936879, DOI: 10.1126/sciadv.adk0785.Peer-Reviewed Original ResearchConceptsMethyltransferase mixed-lineage leukemia 1Cell migrationControls actin filament assemblyRegulation of cell migrationHistone methyltransferase mixed-lineage leukemia 1Actin filament assemblyCell cycle-related pathwaysCancer cell migrationMixed-lineage leukemia 1Regulating cell proliferationMyosin contractilityFilament assemblyProtein meninAssociated with immune cellsMetastatic burdenCancer cellsCell proliferationPrimary tumor growth rateLung metastatic burdenTumor growth rateGrowth rateCellsPreexisting metastasesMetastatic diseaseTumor growth
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply